These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 33587542)
1. Randomized Clinical Trial or Real-World Evidence: How Historical Events, Public Demand, and the Resulting Laws and Regulations Shaped the Body of Medical Evidence. Mackowiak JI; Mack CD; Irwin DE; Zura R J Orthop Trauma; 2021 Mar; 35(Suppl 1):S17-S21. PubMed ID: 33587542 [TBL] [Abstract][Full Text] [Related]
2. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics. Klonoff DC J Diabetes Sci Technol; 2020 Mar; 14(2):345-349. PubMed ID: 30862182 [TBL] [Abstract][Full Text] [Related]
3. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs. Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780 [TBL] [Abstract][Full Text] [Related]
4. The use of real-world evidence to support FDA post-approval study requirements for oncology drugs. Zettler ME Expert Rev Anticancer Ther; 2022 Jun; 22(6):657-666. PubMed ID: 35512688 [TBL] [Abstract][Full Text] [Related]
5. The use of real-world data/evidence in regulatory submissions. Song F; Zang C; Ma X; Hu S; Sun Q; Chow SC; Sun H Contemp Clin Trials; 2021 Oct; 109():106521. PubMed ID: 34339865 [TBL] [Abstract][Full Text] [Related]
6. Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical Review. Seifu Y; Gamalo-Siebers M; Barthel FM; Lin J; Qiu J; Cooner F; Ruan S; Walley R Ther Innov Regul Sci; 2020 Nov; 54(6):1436-1443. PubMed ID: 32514737 [TBL] [Abstract][Full Text] [Related]
7. Real-World Evidence in the Real World: Beyond the FDA. Krause JH; Saver RS Am J Law Med; 2018 May; 44(2-3):161-179. PubMed ID: 30106647 [TBL] [Abstract][Full Text] [Related]
8. Examining the Use of Real-World Evidence in the Regulatory Process. Beaulieu-Jones BK; Finlayson SG; Yuan W; Altman RB; Kohane IS; Prasad V; Yu KH Clin Pharmacol Ther; 2020 Apr; 107(4):843-852. PubMed ID: 31562770 [TBL] [Abstract][Full Text] [Related]
9. Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of American Society of Interventional Pain Physicians (ASIPP). Manchikanti L; Centeno CJ; Atluri S; Albers SL; Shapiro S; Malanga GA; Abd-Elsayed A; Jerome M; Hirsch JA; Kaye AD; Aydin SM; Beall D; Buford D; Borg-Stein J; Buenaventura RM; Cabaret JA; Calodney AK; Candido KD; Cartier C; Latchaw R; Diwan S; Dodson E; Fausel Z; Fredericson M; Gharibo CG; Gupta M; Kaye AM; Knezevic NN; Kosanovic R; Lucas M; Manchikanti MV; Mason RA; Mautner K; Murala S; Navani A; Pampati V; Pastoriza S; Pasupuleti R; Philip C; Sanapati MR; Sand T; Shah RV; Soin A; Stemper I; Wargo BW; Hernigou P Pain Physician; 2020 Mar; 23(2):E85-E131. PubMed ID: 32214287 [TBL] [Abstract][Full Text] [Related]
10. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment. Timbie JW; Kim AY; Concannon TW Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277 [TBL] [Abstract][Full Text] [Related]
11. Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims. Girman CJ; Ritchey ME; McNeill AM; Sundell KA; Meyer RJ Ther Innov Regul Sci; 2021 May; 55(3):561-567. PubMed ID: 33507517 [TBL] [Abstract][Full Text] [Related]
13. AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval. J Manag Care Spec Pharm; 2017 Jan; 23(1):105-112. PubMed ID: 28025919 [TBL] [Abstract][Full Text] [Related]
14. Impact of Federal Regulatory Changes on Clinical Pharmacology and Drug Development: the Common Rule and the 21st Century Cures Act. Burris JF; Puglisi JT J Clin Pharmacol; 2018 Mar; 58(3):281-285. PubMed ID: 28981164 [TBL] [Abstract][Full Text] [Related]
15. Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong? Thompson D Value Health; 2021 Jan; 24(1):112-115. PubMed ID: 33431143 [TBL] [Abstract][Full Text] [Related]
16. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
17. Baby doe redux? The Department of Health and Human Services and the Born-Alive Infants Protection Act of 2002: a cautionary note on normative neonatal practice. Sayeed SA Pediatrics; 2005 Oct; 116(4):e576-85. PubMed ID: 16199687 [TBL] [Abstract][Full Text] [Related]
18. Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions. Sheffield KM; Dreyer NA; Murray JF; Faries DE; Klopchin MN J Comp Eff Res; 2020 Oct; 9(15):1043-1050. PubMed ID: 32914653 [TBL] [Abstract][Full Text] [Related]
19. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions. Wu J; Wang C; Toh S; Pisa FE; Bauer L Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065 [TBL] [Abstract][Full Text] [Related]
20. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia. Webster J; Smith BD Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]